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Aims Thoracoscopic surgical ablation has evolved into a successful strategy for symptomatic atrial fibrillation (AF) refrac-
tory to other therapy. More widespread referral is limited by the lack of information on potential complications.
Our aim was to systematically evaluate 30-day complications of totally thoracoscopic surgical ablation.
...................................................................................................................................................................................................
Methods
and results
We retrospectively studied consecutive patients undergoing totally thoracoscopic surgical ablation at a referral
centre in the Netherlands (2007–2016). Patients received pulmonary vein isolation, with additional lesion lines as
needed, and left atrial appendage exclusion. The primary outcomes were freedom from any complications and free-
dom from irreversible complications at 30-days. Secondary outcomes included intra- and post-operative complica-
tions according to severity. Included were 558 patients with median age 62 years (interquartile range 56–68 years),
70% male and 53% with a previous failed catheter ablation. The cohort consisted of 43% paroxysmal AF, 47%
persistent AF, and 10% long-standing persistent AF. Freedom from any 30-day complication was 88.2%, and from
complications with life-long affecting consequences 97.5%. The intra-operative complication rate was 2.3% with no
strokes or death observed. The median hospital length of stay was 4 days. The percentage of patients with major
and minor complications at 30-days was 3.2% and 8.1%, respectively, with one patient dying of an ischaemic stroke.
The only patient groups with excess complications were women aged >_70 years and patients with a history of con-
gestive heart failure.
...................................................................................................................................................................................................
Conclusions Totally thoracoscopic ablation is associated with a low complication rate in a referral centre and may be a useful
alternative to other rhythm control strategies.
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Introduction
Atrial fibrillation (AF) is common, becoming more prevalent,1 and is
associated with poor quality of life and adverse prognosis.2
Numerous techniques for rhythm control of AF are available to clini-
cians, including electrical cardioversion, anti-arrhythmic drug (AAD)
therapy, catheter (endocardial) ablation and surgical AF (epicardial)
ablation, and hybrid approaches.2 All of these options have potential
risks and complications, but direct comparison is difficult due to the
heterogeneity of patients referred for each procedure.
As highlighted by the rapid increase in patients undergoing
catheter ablation worldwide, rhythm control is a vital component of
effective AF management to alleviate the burden of AF symptoms.
However, many patients develop recurrent AF after catheter
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ablation, are unsuitable for the procedure, need left atrial appendage
(LAA) closure, or prefer a more durable intervention. Totally thora-
coscopic surgical ablation has evolved over a number of years
towards a successful, minimally invasive treatment for AF, typically in
patients with refractory, symptomatic AF. A randomized trial found
that thoracoscopic ablation was superior to catheter ablation in
terms of restoration of sinus rhythm,3 and other studies have shown
a 2-year success rate of 70–80% for preventing recurrent AF.4
However, the complication rate associated with thoracoscopic abla-
tion is less clear yet would seem to be higher than catheter
ablation.4,5
While further randomized trials should be the means for gaining
additional information on rhythm efficacy using thoracoscopic abla-
tion, observational and registry data are able to provide information
on complications more relevant to clinical patients undergoing these
procedures. Our objective was to systematically assess and report
the 30-day complication rate associated with totally thoracoscopic
surgical ablation independently from rhythm outcome, in order to
provide cardiologists and referring physicians with adequate informa-
tion to inform their choice of rhythm control therapy. Further, we
aim to set a standard for future reporting of complications in the field
of thoracoscopic AF ablation surgery.
Methods
Patient selection
We included all consecutive patients who underwent totally thoraco-
scopic epicardial AF ablation in the period from 2007 until January 2016
in a major referral centre in the Netherlands. Patients were discussed in a
multi-disciplinary team; those that required other thoracic or cardiac sur-
gery were instead referred for Cox-maze III/IV surgery. The referral unit
accepts patients from across the country and is a leading European centre
for thoracoscopic and surgical AF ablation. In this period, all procedures
were performed by five surgeons. The study was granted approval by the
medical ethics committee of the St. Antonius Hospital (reference number
W16.011), without the need for informed consent from individual
participants.
Data and outcomes
Medical charts and records were collated for all patients, including demo-
graphics, operation notes, post-operative data, and details of any potential
complications. When patients were referred from other centres, these
centres were contacted to confirm complications during the 30-day post-
operative period. All complications were critically appraised by an event
committee consisting of the lead researcher (L.V.) and two experienced
cardiothoracic surgeons (G.G. and B.P.). In cases of disagreement, a consen-
sus decision was recorded by the surgical panel (G.C., B.P., W.B., F.H., and
B.M.), with the surgeons blinded to patient details. See the Supplementary
material online, Table S1 for details of how each complication was assessed.
The primary outcome for this study was freedom from complications
at 30-days, divided into any complications (intra- or post-operative) and
those with life-long affecting consequences (defined as death, strokes,
venous lung infarction, permanent phrenic nerve paralysis, pacemaker
implantation, renal failure necessitating dialysis, atrium-oesophagus fistula,
and myocardial infarction). For mortality, all patients were checked with
the Dutch civil register. Secondary outcomes were intra-operative
complications and major and minor post-operative complications. Intra-
operative complications were defined as a conversion to (mini)-sternot-
omy or (mini)-thoracotomy, or premature abortion of the operation
because of bleeding. Post-operative complications (up to 30 days) were
classified as major for those likely to result in prolonged hospitalization,
long-term disability, or death. These included cerebral adverse events
(stroke or transient ischaemic attack), re-interventions (e.g. for haemo-
thorax or tamponade), re-intubation (with or without haemodynamic
instability), embolic events (lung or peripheral embolism), pulmonary vein
stenosis, atrium-oesophageal fistula, permanent phrenic nerve paralysis,
renal failure necessitating dialysis, myocardial infarction, and sepsis. Minor
post-operative complications included pericardial effusion necessitating
drainage, permanent pacemaker implantation, the need for a temporary
thoracostomy drain, culture proven infectious complications (urinary tract
or airway, except for wound infections, which were scored when clear
signs of infection were present and antibiotic or interventional treatment
was necessary) and delirium. Conservatively treated pneumothorax was
not considered a complication because it is a direct consequence from
collapsing the lung and CO2 pressure used during the operation. Atrial
rhythm disturbances were not counted as complications during the 30-
day post-operative period, in line with the Heart Rhythm Society consen-
sus statement, which takes a 3-month blanking period into account.5
Surgical procedure
The surgical technique of the totally thoracoscopic surgical ablation has
been described by our group previously.6 Briefly, patients were posi-
tioned in supine position and operated under general anaesthesia and
ventilated with a double-lumen endotracheal tube. A bilateral totally
thoracoscopic epicardial ablation approach was applied. The thoracic
cavity was inflated with CO2 (8 mmHg, 6 L/min). Pulmonary vein isolation
(PVI) was performed with the AtriCure Isolator Synergy ablation clamp
(AtriCure Inc, West Chester, OH, USA). With the evolution of the pro-
cedure over the years, technical aspects of the procedure evolved, includ-
ing variation in lesion sets, selected by discretion of the operator.
However, all patients received epicardial PVI (including those with prior
endocardial PVI from catheter ablation), with additional lesions as
described in Table 1. Additional lesions were made with the AtriCure
Isolator Transpolar Pen (AtriCure, Inc., West Chester, OH, USA), the
Cool rail (Atricure Inc., West Chester, OH, USA), or the multifunctional
linear pen (Atricure, Inc., West Chester, OH, USA). A bidirectional block
(entry/exit block) of the pulmonary veins was confirmed in all patients.
From both sides, entry block was tested by sensing the ipsilateral pulmo-
nary veins with the use of the AtriCure Isolator Transpolar Pen (Atricure
What’s new?
• This is the first comprehensive assessment of complication
rates with thoracoscopic ablation in a large cohort of patients
operated across a 9-year interval in a dedicated atrial fibrilla-
tion centre.
• Overall complication rates were low and mostly procedure-
related and manageable.
• Uniquely due to the large sample size, we were also able to
explore patient factors associated with complication risk. Only
older female patients aged 70 years or above, and those with
history of congestive heart failure had increased risk.
• A scheme for comprehensive complication reporting in thora-
coscopic surgical ablation was provided, that could also be
adapted for other surgical studies to aid clinical decision mak-
ing and comparison of safety with different treatment options.
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Inc, West Chester, OH, USA). Exit block was confirmed by pacing the
pulmonary veins after cardioversion in case of AF. In case of creation of
an additional posterior box, exit block was tested from the left side, and
confirmed when ventricular capture was not observed on ECG monitor-
ing while pacing non-ablated tissue within the box, with a maximum out-
put of 25 mA. In case of ventricular capture, additional ablation was
performed until exit block could be confirmed. The LAA was excluded in
all patients as a standard procedure for stroke prevention and as part of
the ablation lesion set to eliminate any potential pro-arrhythmic triggers
from the LAA. Exclusion of the LAA was achieved with the Endo-Gia sta-
pler (Tyco Healthcare Group, North Haven, CT, USA), loop stitches, or
more recently the AtriClip (Atricure Inc., West Chester, OH, USA).
Post-operative care and follow-up
Anti-arrhythmic drugs were post-operatively adjusted according to the
individual patient’s heart rate and rhythm. In general, pre-operative
rhythm medication was continued after the procedure at least for the
length of the blanking period. Patients received oral anticoagulation
(OAC) after surgery at least for the length of the blanking period. In case
of persisting post-operative AF during admission, at least one attempt to
restore sinus rhythm with electrical cardioversion was performed. After
discharge, management of AAD and OAC were left to the discretion of
the referring cardiologist.
Statistical analysis
Descriptive statistics are given as percentages, medians with interquartile
range (IQR), or mean and standard deviation (SD). Continuous variables
were analysed with the Mann–Whitney U test and categorical data with
the v2 test, or the Fisher’s exact test for low expected counts (<5).
Freedom from complication events were demonstrated using the
Kaplan–Meier plots for all patients and according to subgroups of clinical
importance [previous catheter ablation, baseline body mass index (BMI),
left ventricular ejection fraction, and a history of congestive heart failure].
Multivariate analysis of patient variables associated with freedom from
any complications at 30-days was performed with the Cox proportional
hazards model, including age, gender, prior stroke/transient ischaemic
attack (TIA)/embolus, BMI, duration of AF, type of AF, CHA2DS2-VASc
score and history of hypertension, diabetes, heart failure, and previous
failed catheter ablation. Three patients had missing data on heart failure
status and two patients had missing BMI. Schoenfeld residuals were used
to confirm proportionality over time and interactions were assessed in
bivariate and multivariate Cox and logistic regression models. Statistical
analysis used SPSS (version 22.0; SPSS Inc., Chicago, IL, USA) and Stata
(version 14.2; StataCorp LP, College Station, TX, USA). A two-tailed
P-value <0.05 was considered statistically significant.
Results
Five hundred and fifty-eight patients were included in our analysis,
with median age 62 years (IQR 56–68 years) and 70% male. Patient
characteristics and procedural details are shown in Table 1.
Paroxysmal AF was present in 43% and 53% of patients had a history
of failed previous catheter ablation (mean number of 1.7 proce-
dures). The average duration of AF was 5 years and the mean
CHA2DS2-VASc score was 1.4 (SD 1.3; range 0–6). All patients
received PVI, with additional lesions applied in the majority of
patients (Table 1). The LAA was excluded in all but 12 patients
(97.5%); the reasons for not excluding the LAA were prior watchman
device implantation (n= 4), adhesions (n= 4), poor exposure (n= 2),
request by the patient (n= 1), and an aborted procedure due to
bleeding (n= 1). The median hospital length of stay was 4 days (IQR
3–6). During the admission, 30.5% of patients (170/558) developed at
least one episode of AF, flutter, or another atrial tachyarrhythmia. At
discharge, 12.5% (70/558) were in AF. A proportion of these patients
were scheduled for electrical cardioversion in the outpatient setting
due to inadequate anticoagulation status during admission, or due to
patient preference.
Primary outcome and mortality
Overall freedom from any 30-day complications was 88.2% (492/
558); Figure 1A. Freedom from complications with life-long affecting
consequences (defined as death, strokes, venous lung infarction, per-
manent phrenic nerve paralysis, and pacemaker implantation) was
97.5% (544/558); Figure 1B. No patients died during their operation.
One patient died within 30 days; this patient was discharged after
4 days of an uncomplicated hospital stay for PVI and LAA exclusion.
Three weeks later this patient was re-admitted because of an ischae-
mic stroke in sinus rhythm, but with an inadequately regulated inter-
national normalized ratio and subsequently died.
.................................................................................................
Table 1 Patient characteristics and procedural details
Characteristics Total (n5 558)
Age (years), median (IQR) 62 (56–68)
Male gender, n (%) 392 (70.3)
Body mass index (kg/m2), median (IQR) 27.1 (24.8–29.8)
Type of AF, n (%)
Paroxysmal 238 (42.7)
Persistent 265 (47.5)
Long-standing persistent 55 (9.9)
Left ventricular ejection fraction, n (%)
>_50% 505 (90.5)
40–49% 36 (6.5)
<40% 17 (3.0)
Duration of AF (years), median (IQR) 5.1 (2.8–9.4)
History of >_1 failed catheter ablation, n (%) 295 (52.9)
Pre-operative pacemaker, n (%) 34 (6.1)
Pre-operative cerebral events, n (%):
Transient ischaemic attack 32 (5.7)
Ischaemic stroke 30 (5.4)
Haemorrhagic stroke 7 (1.3)
Procedural details
Confirmed pulmonary vein isolation, n (%) 555 (99.5)
Additional lesions, n (%)
Roof linea 64 (11.5)
Posterior box 431 (77.2)
Trigone 277 (49.6)
>_1 other additional lesionb 76 (13.6)
Ganglionic plexus ablation 365 (65.4)
Left atrial appendage exclusion, n (%) 549 (98.4)
AF, atrial fibrillation; IQR, interquartile range.
aRoofline without floorline.
bFor example, Bicaval and/or right atrial lesion.
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Intra-operative complications
Operative complications occurred in 2.3% of patients (13/558)
related to conversions for bleeding including sternotomy, mini-ster-
notomy, and mini-thoracotomy (Table 2). In one patient the opera-
tion was aborted before any ablation took place, because of bleeding
of the pulmonary artery. No intra-operative strokes occurred.
Major post-operative complications
Major complications occurred in 3.2% (n= 18) of the patients
(Table 3). Re-interventions were performed in 1.6% of the patients
(n= 9) due to haemothorax or pericardial effusion/tamponade, and
one patient developed an empyema after pleural fluid drainage. One
patient had a TIA, and another patient had an ischaemic stroke (with
only mild aphasia once recovered). Sub-segmental lung embolus
(subsequently fully recovered) was encountered twice and perma-
nent phrenic nerve paralysis was encountered once. One patient had
a venous lung infarction; this patient was re-intubated for respiratory
insufficiency. The medical history of this patient included four cathe-
ter ablations, so (partial) pulmonary vein stenosis may already have
been pre-existent. Two other patients were also re-intubated for
reasons of bilateral pneumothorax and haemodynamic instability
without known cause and subsequently were discharged without any
sequelae.
Minor post-operative complications
Minor complications occurred in 8.1% (n= 45) of the patients
(Table 3), including chest drainage (3.6%, n= 20), pericardiocentesis
without clinical signs of tamponade (0.7%, n= 4), and permanent
pacemaker implantation (1.8%, n= 10; all due to sick sinus
syndrome).
Factors associated with any complication
after thoracoscopic ablation
We identified an interaction between age and gender for the devel-
opment of complications after thoracoscopic surgical ablation. While
the complication rate in men was similar across all ages, women had
lower complication rates at younger ages and higher rates than men
at the age of 70 or above (Figure 2).
There were no differences in complications in those with or with-
out preceding endocardial catheter ablation (Figure 3A). Similarly, BMI
was not significantly associated with complications (Figure 3B);
numerically, those with obesity had the lowest complication rate.
Left-ventricular ejection fraction was unrelated to complications
(Figure 3C). Although only present in a small number of patients and
hence exploratory, congestive heart failure was associated with
adverse outcomes in the Kaplan–Meier analysis (Figure 3D) and multi-
variate regression (Supplementary material online, Table S2; hazard
ratio 5.08, 95% CI 1.42–18.18; P= 0.012).
Complications, hospital length of stay,
and readmissions
The length of hospital stay was not different for patients with intra-
operative complications compared to those with an uneventful intra-
operative course [median duration of 5 days (IQR 3–11) compared
to 4 days (IQR 3–6) respectively; P= 0.12]. However, patients with
at least one post-operative complication had significantly longer
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Figure 1 The Kaplan–Meier event curves for (A) freedom from any complications and (B) those with life-long consequences at 30-days.
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Table 2 Intra-operative complications
Complication n (%)
Mortality 0 (0.0)
Stroke 0 (0.0)
Transient ischaemic attack 0 (0.0)
Sternotomy for bleeding 9 (1.6)
Mini-sternotomy for bleeding 2 (0.4)
Mini-thoracotomy for bleeding 1 (0.2)
Bleeding with discontinuation of procedure 1 (0.2)
Total number of intra-operative complications, n (%) 13/558 (2.3)
4 L.M. Vos et al.
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hospitalization compared to those without any post-operative com-
plications [8 days (IQR 5–10) vs. 4 days (IQR 3–6), respectively;
P< 0.001). Nineteen patients (3.4%) were re-admitted within 30 days
of thoracoscopy [median duration of 3 days (IQR 2–7)], with the
majority admitted for additional diagnostics (e.g. rhythm observation,
lung imaging with chest X-ray, or computed tomography). Four of
these patients were classified as having a complication of the thoraco-
scopic ablation and are included as post-operative complications
above.
Learning curve effects
Complications were analysed over time to assess the potential learn-
ing curve of totally thoracoscopic surgical ablation. Figure 4 shows the
post-operative complications from 2008 to 2015, highlighting a
downward trend in the overall post-operative complication rate in
our specialist referral centre.
Discussion
This is the first comprehensive assessment of totally thoracoscopic
epicardial ablation complications, performed with critical appraisal on
a case-by-case basis in a large cohort of patients operated across a
9-year interval. Our study showed that 88.2% of our patients were
free from any complication at 30 days. The majority of complications
that occurred were transient and the freedom from irreversible com-
plications further affecting a patient’s long-term prognosis was 97.5%.
No operative mortality or stroke was observed, although one patient
with poor INR control suffered a stroke and died during follow-up
(mortality rate 0.2%). Post-operative complications were mostly
procedure-related and manageable with conventional treatment.
Previous thoracoscopic surgical ablation studies have focused on
rhythm outcomes and only included complications as a secondary
safety outcome. We speculate that this might have resulted in over-
and under-estimation of complication rates in some series, which
range widely from 0 to 34%.4,5,7–10 This variation in complication
rates can further be explained by the small size of patient numbers
included in past reports and by the limited amount of operators
involved. In contrast, we systematically catalogued complications
from all consecutive patients operated on in our referral centre by
multiple surgeons without any patient selection, and identified low
rates of mortality, stroke and 30-day complications.
Uniquely due to the large sample size, we were also able to
explore patient factors associated with complication risk. Neither the
type of AF, history of previous catheter ablation, nor ejection fraction
was related to complications, and our analysis refuted the commonly
held belief that obesity increases complication risk. Only older female
patients aged 70 years or above, and those with history of congestive
heart failure, had increased risk. With respect to heart failure, these
.................................................................................................
Table 3 Post-operative complications
n (%)
Major complications
Death 1 (0.2)
Reinterventionsa
Haemothorax 7 (1.3)
Pericardial effusion/tamponade 1 (0.2)
Empyema 1 (0.2)
Re-intubation without haemodynamic instability 1 (0.2)
Re-intubation due to haemodynamic instability 2 (0.4)
Venous lung infarction 1 (0.2)
Lung emboli 2 (0.4)
Permanent phrenic nerve paralysis 1 (0.2)
Stroke 1 (0.2)
Transient ischaemic attack 1 (0.2)
Atrium-oesophagus fistula 0 (0.0)
Myocardial infarction 0 (0.0)
Renal failure necessitating dialysis 0 (0.0)
Sepsis 0 (0.0)
Total number of patients with >_1 major complication 18 (3.2)
Total number of major complications 19 (3.4)
Minor complications
Pericardial fluid necessitating pericardiocentesis 4 (0.7)
Permanent pacemaker implantation 10 (1.8)
Thoracostomy drain for
Pneumothorax 12 (2.2)
Pleural effusion 6 (1.1)
Haemothorax 2 (0.4)
Infections
Airway infection 7 (1.3)
Urinary tract infection 2 (0.4)
Superficial wound infection 1 (0.2)
Delirium 1 (0.2)
Gastrointestinal bleeding 1 (0.2)
Total number of patients with >_1 minor complication 45 (8.1)
Total number of minor complications 46 (8.2)
aIncluding thoracotomy, sternotomy, or video-assisted-thoracoscopic surgery.
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patients should be adequately treated according to the latest evi-
dence prior to undergoing any rhythm control procedure.11,12
Rhythm control is an important part of the management of AF and
is targeted to improve symptoms, rather than prognosis. The 2016 AF
guidelines from the European Society of Cardiology (ESC) give a
Class IIa (B) recommendation for epicardial PVI for patients with
symptomatic AF after failed catheter ablation, and IIa (C) for other
patients with refractory symptomatic persistent AF.2 Decisions involv-
ing surgery should be supported by an AF Heart Team that includes
experienced cardiologists, electrophysiologists, and AF surgeons, to
advise patients on available options for rhythm control.13 As all deci-
sions on rhythm control must balance the risk of complications with
symptomatic benefit, our systematic appraisal of complications in this
large series is vital for the AF Heart Team to decide on whether AAD,
(repeat) catheter ablation, or thoracoscopic ablation is more
appropriate for individual patients. Comparison between thoraco-
scopic and catheter ablation is limited by the heterogeneity of patients
and different techniques (endocardial vs. epicardial approach); how-
ever, our data would suggest comparable complication rates. The
FAST trial is one of only three prospective randomized trials that have
compared catheter with thoracoscopic ablation, reporting a higher
success rate but also a higher complication rate after surgical ablation,
mainly due to a higher incidence of conservatively treated pneumo-
thorax.3 Catheter ablation is associated with severe complications in
5–7%, and 2–3% will experience life-threatening but usually manage-
able complications.2 Thoracoscopic surgical ablation is a more invasive
procedure with associated surgical complications, but does not result
in radiation exposure.14,15 Atrial-oesophageal fistula is an exception-
ally rare complication after thoracoscopic ablation surgery that can be
avoided with good surgical technique.16
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Clinical perspective
Since the first description of thoracoscopic surgical ablation in 2003,
this technique has evolved from PVI only towards routine use of
extended lesion sets. Although thoracoscopic ablation is recom-
mended as an alternative to catheter ablation in certain categories of
patients, the procedure is not widely available at present. However,
there is a growing trend towards less invasive surgical access and
thoracoscopic approaches in particular. Whilst patients currently
have to be referred to dedicated referral centres and have a longer
inpatient hospital stay than catheter ablation, it is anticipated that
thoracoscopic ablation will become more accessible in the near
future because of its effectiveness for long-term rhythm control. Our
data confirm a short learning curve with further reduction in compli-
cation rates with ongoing experience.
The introduction of thoracoscopic ablation surgery was driven by
the need for less invasive strategies that could replace the Cox-maze
III/IV operation, which although effective, requires extra-corporal cir-
culation and cardiac arrest. Balancing this, thoracoscopic ablation
provides a less complete lesion set than conventional surgery due to
limited access to cardiac structures, and hence lower success rates
for maintenance of sinus rhythm.17 The Cox-maze III/IV operation
can also be performed by a minimally invasive approach in many
centres avoiding the need for sternotomy, although reported compli-
cation rates are higher than our series.17 No data comparing this
approach with thoracoscopic ablation are available, and the Cox-
maze III/IV operation is not a viable alternative to catheter ablation
for most patients.
Limitations, strengths, and future studies
The main limitations of our analysis were the observational nature
and retrospective design. Although we systematically assessed com-
plications after totally thoracoscopic ablation surgery, there is a risk
of incomplete data or bias with this approach. We did not consider
adverse events relating to AAD therapy and also limited our
assessment to 30-day complications. However, we would expect to
capture most, if not all operative complications at this point, and the
data can be more easily compared with other procedures with
30-day outcomes. We consider the heterogeneity of patients and
procedures a strength of this analysis, as the complication rate is
more likely to reflect clinical practice than studies with strict inclusion
criteria. Thoracoscopic ablation typically uses an array of lesion sets6;
although our study is unable to determine whether this approach
increases the risk of complications beyond PVI alone, additional
lesions may yield incremental value for rhythm control and most
patients have already failed conventional endocardial PVI. Our
surgeons were clearly not blinded to operative outcomes, although
bias was minimized by utilizing an independent research fellow to
catalogue complications. Finally, although we collected data from
multiple surgeons consecutively, these were all based at a dedicated
AF surgical centre with a specialized and experienced team of staff.
Therefore, our finding that this procedure can be delivered with a
low and acceptable complication rate may not be generalizable to
other smaller centres or those with a lower volume of referred
patients. Combining data from multiple institutions and generating
longer-term data on the maintenance of sinus rhythm are the next
steps, after ensuring that the methods of obtaining such data are
robust and systematic. Outcome definition and reporting need to be
standardized, credible, and accurate, in order to correctly inform
patients and referring clinicians. In Supplementary material online,
Table S1,18–20 we provide a potential scheme for comprehensive
complication reporting in thoracoscopic surgical ablation, which
could also be adapted for other surgical studies to encourage consis-
tent reporting of complications.
Conclusion
Totally thoracoscopic epicardial ablation has evolved towards a safe
surgical treatment for refractory symptomatic AF and is associated
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with a low complication rate in an AF surgical centre. The majority of
complications relating to this procedure were reversible and not
expected to adversely affect patient prognosis. Where suitably
trained thoracoscopic surgeons are available, thoracoscopic surgical
ablation should be considered a viable alternative or adjunct to cathe-
ter ablation to improve symptoms related to recurrent AF.
Supplementary material
Supplementary material is available at Europace online.
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Supplementary Table 1: Systematic complication reporting of thoracoscopic AF ablation 
Intra-operative 
complications 
 
Mortality Mortality during surgery. The cause of death should be provided. 
Stroke New or worsened neurologic deficit that is present after the patient emerged 
from anaesthesia. The term 'stroke' should include central nervous system 
(CNS) infarction, and includes: brain, spinal cord, or retinal cell death 
attributable to ischaemia, based on 1. pathological, imaging, or other 
objective evidence of CNS ischaemic injury in a defined vascular 
distribution; or 2. clinical evidence of CNS ischaemic injury based on 
symptoms persisting ≥24 hours or until death, and other aetiologies excluded. 
(Note: CNS infarction includes haemorrhagic infarctions). The diagnosis 
should be confirmed by a neurologist.18  
Transient ischaemic attack  New or worsened neurologic deficit that is present after the patient emerged 
from anaesthesia. Transient ischaemic attack (TIA) is defined as complete 
resolution of neurological symptoms usually within 1-2 hours but always < 
24 h and also requires a normal neuroimaging study. Scoring of TIA should 
be done with care because detection is hindered in the immediate 
postoperative period due to residual anaesthetics, analgesics and/or sedative 
drugs. The diagnosis should be confirmed by a neurologist.18 
Conversion to (mini-) 
sternotomy/thoracotomy for 
bleeding 
Intra operative bleeding necessitating conversion to either sternotomy or 
thoracotomy (with or without the use of extra-corporal circulation) to 
adequately stop the bleeding.  
Incomplete lesions due to 
bleeding 
Bleeding with abortion of the procedure before the pre-operative intended 
lesions are completed.  
Post-operative 
complications 
Complications in the postoperative period at least including 30-day 
follow-up. 
1. Major complications  
Mortality  Mortality that occurs during the postoperative period. Time of death, cause 
of death and relevant clinical information should be provided.   
Reinterventions Re-interventions (either sternotomy, subxyphoid incision, thoracotomy or 
video assisted thoracoscopic procedures) for reasons related to thoracoscopic 
epicardial ablation such as haemothorax, pneumothorax, pericardial effusion 
or empyema. The indication for re-intervention should be provided.  
Reintubation with 
haemodynamic instability 
Re-intubation due to an instable haemodynamic setting of the patient, for 
example caused by rhythm disturbances or decompensation.  
Reintubation without 
haemodynamic instability 
Re-intubation in a stable haemodynamic patient (e.g. for primary pulmonary 
indications).  
Lung emboli Lung emboli confirmed with Computed Tomography imaging. 
Permanent phrenic nerve  Persisting phrenic nerve paralysis 1 year after surgery confirmed by 
Fluoroscopic examination of the diaphragm ("sniff test").  
Pulmonary vein stenosis Symptomatic pulmonary vein stenosis (>65%) as a result from thoracoscopic 
epicardial ablation confirmed with Computed Tomography imaging.19 
Stroke Cerebral events are scored as postoperative complication when the patient 
developed the neurological deficit after first awaking from surgery without a 
neurological deficit. New or worsened neurologic deficit that is present after 
the patient emerged from anaesthesia. The term 'stroke' should include 
central nervous system (CNS) infarction, and includes: brain, spinal cord, or 
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retinal cell death attributable to ischaemia, based on 1. pathological, imaging, 
or other objective evidence of CNS ischaemic injury in a defined vascular 
distribution; or 2. clinical evidence of CNS ischaemic injury based on 
symptoms persisting ≥24 hours or until death, and other aetiologies excluded. 
(Note: CNS infarction includes haemorrhagic infarctions). The diagnosis 
should be confirmed by a neurologist.18 
Transient ischaemic attack Cerebral events are scored as postoperative complication when the patient 
developed the neurological deficit after first awaking from surgery without a 
neurological deficit. Transient ischaemic attack (TIA) is defined as complete 
resolution of new neurological symptoms usually within 1-2 hours but 
always < 24 h and also requires a normal neuroimaging study. Scoring of 
TIA should be done with care because detection is hindered directly 
postoperative to residual anaesthetics, analgesics and/or sedative drugs. The 
diagnosis should be confirmed by a neurologist.18 
Atrium-oesophagus fistula Continued and/or repeated massive thermal injury during ablation techniques 
can induce fistula formation with delayed onset of typical symptoms such as 
fever, malaise, dysphagia, haematemesis/melena, neurological deficits, 
intermittent cardiac ischaemia or septic shock. The diagnosis should be 
confirmed by atrium-oesophagus fistula compatible findings on Computed 
Tomography of the chest with intravenous contrast.20  
Renal failure necessitating 
dialysis 
Acute kidney injury should be scored as major complication if it met the 
criteria of stage 3 acute kidney injury: initiation of renal replacement therapy, 
or increase in serum creatinine to ≥3.0 times baseline or ≥4.0 mg/dl  (≥353.6 
mmol/l).   
Myocardial infarction Acute myocardial infarction (MI) should be scored if there is evidence of 
myocardial necrosis in a clinical setting consistent with acute myocardial 
ischaemia. Under these conditions any one of the following criteria meets the 
diagnosis for MI: 1) Ischaemic changes on ECG (new or presumed new 
significant ST-segment- T wave changes or new left bundle branch block, 
development of pathological Q waves), 2) Imaging evidence of new loss of 
viable myocardium or new regional wall motion abnormality, 3) 
Identification of an intracoronary thrombus by angiography or autopsy. Note 
that detection of a rise and/or fall of cardiac biomarker values (Troponin, 
Creatinin Kinase-MB) are less reliable in the context of the thoracoscopic 
epicardial ablation procedure because ablation involves controlled 
myocardial injury with necrosis, and therefore elevation of these biomarkers 
alone should not be labelled as myocardial infarction. 
2. Minor complications  
Pericardial fluid 
necessitating 
pericardiocentesis 
Pericardial fluid necessitating pericardiocentesis. 
Permanent pacemaker 
implantation 
Permanent pacemaker implantation for sick sinus syndrome. Patients that 
were considered for pacemaker implantation pre-operatively should not be 
scored as complication. 
Thoracostomy drain for 
different indications 
The insertion of a thoracostomy drain in the postoperative period should be 
scored as complication, including reporting the indication (e.g. haemothorax, 
pleural effusion, pneumothorax, empyema). Note, conservatively treated 
pneumothorax/pleural effusion/haemothorax should not routinely be 
recorded as a complication.  
Infections  Infections (urinary tract, airway or other except for wound infections) should 
be scored if culture proven. Wound infection should be only scored when 
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clear clinical signs of infection are present and (antibiotic or interventional) 
treatment is necessary.   
Delirium Delirium is defined as an acute and fluctuating disturbance in consciousness, 
characterized by disorientation, a disturbed sleep-wake cycle, memory 
impairment, perceptual disturbances, and altered psychomotor activity. 
Clinical assessment, including validated delirium screening instruments for 
optimal delirium detection should be carried out by a health professional 
competent and trained in the diagnosis delirium (e.g. neurologist or 
geriatrician). 
Blood loss requiring 
transfusion 
Number of transfusion units should be recorded.  
3. Other complications  Other additional complications necessitating treatment (drugs, 
interventional), not specified elsewhere. E.g. gastro-intestinal problems. 
4. Irreversible 
complications 
Those complications with clear life-long affecting consequences (minor or 
major), and should encompass at least the following complications: 
mortality, stroke, pulmonary vein stenosis, atrium-oesophagus fistula, 
myocardial infarction, permanent pacemaker implantation and renal failure 
necessitating dialysis.  
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Supplementary Table 2:  Multivariate analysis for the risk of any complication after 
totally thoracoscopic surgical ablation 
 
Baseline variable Hazard ratio 95% CI p-value 
Age (per 1 year older) * 1.00 0.96 - 1.04 0.91 
Gender (female vs. male) * 0.97 0.50 - 1.92 0.94 
History of stroke, TIA or embolus (yes vs. no) 0.73 0.22 - 2.42 0.61 
Body mass index (per kg/m2) 1.01 0.95 - 1.07 0.86 
Duration of AF (per year) 1.05 1.01 - 1.09 0.017 
Type of AF (persistent vs. paroxysmal) 0.82 0.50 - 1.35 0.43 
History of hypertension (yes vs. no) 1.11 0.54 - 2.29 0.77 
History of diabetes (yes vs. no) 0.49 0.11 - 2.17 0.35 
Previous failed catheter ablation (yes vs. no) 0.81 0.48 - 1.34 0.41 
History of congestive heart failure (yes vs. no) 5.08 1.42 - 18.18 0.012 
CHA2DS2-VASc score (per 1 unit increase) 1.21 0.77 - 1.92 0.41 
 
Cox proportional hazards regression for any 30-day complication.  * An interaction was present for 
age and gender (see Figure 2). 
 
